Literature DB >> 12913256

Alleviating effects of si-ni-san, a traditional Chinese prescription, on experimental liver injury and its mechanisms.

Jieyun Jiang1, Chunxiang Zhou, Qiang Xu.   

Abstract

The present study aims at examining the effects of Si-Ni-San, a prescription usually used for treating hepatitis in Traditional Chinese Medicine (TCM), on various experimental liver injury models and its mechanisms. The prescription showed significant hepatoprotection against CCl(4)-induced hepatic damage, both in vivo and in vitro. To the liver injury induced by Bacillus Calmette-Guerin (BCG) with lipopolysaccharide (LPS), Si-Ni-San also provided significant alleviation through enhancing nitric oxide (NO) release by macrophages. Against the liver injury induced by a delayed-type hypersensitivity reaction to picryl chloride (PCl-DTH), Si-Ni-San alleviated it remarkably when administered during either the induction or effector phase. A significant reduction of in-vitro hepatotoxicity, as measured by the inhibition of serum transaminase evaluation, was observed in nonparenchymal cells from liver-injured mice treated with Si-Ni-San. Si-Ni-San facilitated apoptosis in nonparenchymal cells from liver-injured mice, as well as in spleen cells activated by PCl in vivo or by Con A in vitro. These results suggest that Si-Ni-San provides alleviating effects against liver injury through multiple mechanisms, including protection of the hepatocyte membrane, enhancement of NO release, and dysfunction of liver-infiltrating cells mainly through causing their apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913256     DOI: 10.1248/bpb.26.1089

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Systems Pharmacology Based Study of the Molecular Mechanism of SiNiSan Formula for Application in Nervous and Mental Diseases.

Authors:  Xia Shen; Zhenyu Zhao; Xuan Luo; Hao Wang; Benxiang Hu; Zihu Guo
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-12       Impact factor: 2.629

2.  Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study.

Authors:  Fafeng Cheng; Chongyang Ma; Xueqian Wang; Changming Zhai; Guoli Wang; Xiaolin Xu; Jie Mu; Changxiang Li; Zisong Wang; Xiaoyu Zhang; Wenchao Yue; Xin Du; Yajun Lian; Wenxiang Zhu; Xiangjun Yin; Zhen Wei; Wenjie Song; Qingguo Wang
Journal:  BMC Complement Altern Med       Date:  2017-04-07       Impact factor: 3.659

3.  Literature Review of Traditional Chinese Medicine Herbs-Induced Liver Injury From an Oncological Perspective With RUCAM.

Authors:  Hei Ching Chow; Tsz Him So; Horace Cheuk Wai Choi; Ka On Lam
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

4.  Selective depletion of glycyrrhizin from Si-Ni-San, a traditional Chinese prescription, blocks its effect on contact sensitivity in mice and recovers adhesion and metalloproteinases production of T lymphocytes.

Authors:  Li Zhang; Yang Sun; Ting Chen; Qiang Xu
Journal:  Int Immunopharmacol       Date:  2005-03-21       Impact factor: 4.932

5.  Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.

Authors:  Siliang Wang; Cheng Tang; Heng Zhao; Peiliang Shen; Chao Lin; Yun Zhu; Dan Han
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

6.  The Chinese medicine Sini-San inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells.

Authors:  Hung-Jen Lin; Shung-Te Kao; Yu-Miao Siao; Chia-Chou Yeh
Journal:  BMC Complement Altern Med       Date:  2015-10-07       Impact factor: 3.659

7.  Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan.

Authors:  Qin Zhang; Zhangying Feng; Mengxi Gao; Liru Guo
Journal:  PeerJ       Date:  2021-02-16       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.